Annual study of 5G SA market reveals coverage gap between major economic blocs narrowing by the end of 2025, but with growing signs of more consequential signs of divergent spectrum strategies, ...
Clinical Trials Arena on MSN
Cyrano reports positive data from phase II trial of CYR-064
The study met its primary objective, showing that CYR-064 was safe and well tolerated.
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results